Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
9.39M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
2.6M
-
Shares change
-
+680K
-
Total reported value, excl. options
-
$101M
-
Value change
-
+$26.9M
-
Put/Call ratio
-
0.06
-
Number of buys
-
42
-
Number of sells
-
-13
-
Price
-
$38.97
Significant Holders of Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share (TVRD) as of Q3 2025
74 filings reported holding TVRD - Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q3 2025.
Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share (TVRD) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.6M shares
of 9.39M outstanding shares and own 27.73% of the company stock.
Largest 10 shareholders include Slate Path Capital LP (704K shares), VANGUARD GROUP INC (419K shares), BlackRock, Inc. (330K shares), 683 Capital Management, LLC (176K shares), Vestal Point Capital, LP (167K shares), GEODE CAPITAL MANAGEMENT, LLC (148K shares), Invesco Ltd. (82.6K shares), FMR LLC (82.2K shares), Parkman Healthcare Partners LLC (65K shares), and STATE STREET CORP (62.9K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.